Status:
COMPLETED
Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 ...
Eligibility Criteria
Inclusion
- A diagnosis of psoriatic arthritis
Exclusion
- Patients with arthritis or ankylosing spondyitis
- Drug-induced psoriasis
- Male or female patients who plan to conceive during the time course of the study, or for 6 months after the administration of the second dose.
- Participation in any clinical trial within 4 weeks prior to initial dosing or longer.
- Previous use of immunosuppressive agents eg cyclosporine, without the necessary wash-out period
- History of severe allergy to food or drugs
- Positive TB test. Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00809614
Start Date
March 1 2009
End Date
December 1 2010
Last Update
November 13 2015
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Berlin, Germany, 12203
2
Novartis Investigative Site
Hamburg, Germany, 22081
3
Novartis Investigative Site
Hamburg, Germany, 22415
4
Novartis Investigative Site
Herne, Germany, 44649